Delia M. Talos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Delia M. Talos has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Annapurna Poduri
Harvard Medical School, Boston, Children's Hospital Boston, Boston
1 shared publication- Annelise Joseph
Department of Biology and Center for Behavioral Genomics, Brandeis University, Waltham, Massachusetts 02454
1 shared publication Bela Kosaras
Harvard Medical School, Boston, Children's Hospital Boston, Boston
1 shared publication- Frances E. Jensen
Department of Neurology, Division of Neuroscience, Children’s Hospital, Boston, Massachusetts 02115
1 shared publication Hongyu Sun
Harvard Medical School, Boston, Children's Hospital Boston, Boston
1 shared publicationJoseph R. Madsen
Harvard Medical School, Boston, Children's Hospital Boston, Boston
1 shared publication
Latest Publications
- 16 December 2011
- Published by Wiley in Annals of Neurology
- Vol. 71 (4) , 539-551
Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia
Objective: The most common neurological symptom of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) is early life refractory epilepsy. As previous studies have shown enhanced excitatory glutamatergic neurotransmission in TSC and FCD brains, we hypothesized that neurons associated with these lesions may also express altered γ‐aminobutyric acid (GABA)A receptor (GABAAR)‐mediated inhibition.Methods: Expression of the GABAAR subunits α1 and α4, and the Na+‐K+‐2Cl− (NKCC1) and the K+‐Cl− (KCC2) transporters, in human TSC and FCD type II specimens were analyzed by Western blot and double label immunocytochemistry. GABAAR responses in dysplastic neurons from a single case of TSC were measured by perforated patch recording and compared to normal‐appearing cortical neurons from a non‐TSC epilepsy case.Results: TSC and FCD type IIb lesions demonstrated decreased expression of GABAAR α1, and increased NKCC1 and decreased KCC2 levels. In contrast, FCD type IIa lesions showed decreased α4, and increased expression of both NKCC1 and KCC2 transporters. Patch clamp recordings from dysplastic neurons in acute slices from TSC tubers demonstrated excitatory GABAAR responses that were significantly attenuated by the NKCC1 inhibitor bumetanide, in contrast to hyperpolarizing GABAAR‐mediated currents in normal neurons from non‐TSC cortical slices.Interpretation: Expression and function of GABAARs in TSC and FCD type IIb suggest the relative benzodiazepine insensitivity and more excitatory action of GABA compared to FCD type IIa. These factors may contribute to resistance of seizure activity to anticonvulsants that increase GABAergic function, and may justify add‐on trials of the NKCC1 inhibitor bumetanide for the treatment of TSC and FCD type IIb‐related epilepsy. ANN NEUROL 2012
- 16 December 2011
- Published by Wiley in Annals of Neurology
- Vol. 71 (4) , 539-551
Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia
Objective: The most common neurological symptom of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) is early life refractory epilepsy. As previous studies have shown enhanced excitatory glutamatergic neurotransmission in TSC and FCD brains, we hypothesized that neurons associated with these lesions may also express altered γ‐aminobutyric acid (GABA)A receptor (GABAAR)‐mediated inhibition.Methods: Expression of the GABAAR subunits α1 and α4, and the Na+‐K+‐2Cl− (NKCC1) and the K+‐Cl− (KCC2) transporters, in human TSC and FCD type II specimens were analyzed by Western blot and double label immunocytochemistry. GABAAR responses in dysplastic neurons from a single case of TSC were measured by perforated patch recording and compared to normal‐appearing cortical neurons from a non‐TSC epilepsy case.Results: TSC and FCD type IIb lesions demonstrated decreased expression of GABAAR α1, and increased NKCC1 and decreased KCC2 levels. In contrast, FCD type IIa lesions showed decreased α4, and increased expression of both NKCC1 and KCC2 transporters. Patch clamp recordings from dysplastic neurons in acute slices from TSC tubers demonstrated excitatory GABAAR responses that were significantly attenuated by the NKCC1 inhibitor bumetanide, in contrast to hyperpolarizing GABAAR‐mediated currents in normal neurons from non‐TSC cortical slices.Interpretation: Expression and function of GABAARs in TSC and FCD type IIb suggest the relative benzodiazepine insensitivity and more excitatory action of GABA compared to FCD type IIa. These factors may contribute to resistance of seizure activity to anticonvulsants that increase GABAergic function, and may justify add‐on trials of the NKCC1 inhibitor bumetanide for the treatment of TSC and FCD type IIb‐related epilepsy. ANN NEUROL 2012